CDK4/6 Inhibition Plus Aromatase Inhibition in Advanced Breast Cancer
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
PALOMA-2 Phase III Trial Results
- June 20, 2016
Palbociclib (Ibrance, CDK4/6 inhibitor) combined with letrozole demonstrated superior efficacy versus letrozole monotherapy in first-line treatment of ER+/HER2- advanced breast cancer in postmenopausal women.
Key Efficacy Data
Progression-Free Survival:
- Palbociclib + Letrozole: 24.8 months
- Placebo + Letrozole: 14.5 months
- 42% risk reduction (p<0.000001)
Objective Response Rate:
- Combination: 85%
- Letrozole alone: 70% (p<0.0001)
Safety Profile
Common Grade 3-4 adverse events: neutropenia (6%), fatigue (28%), nausea (26%), arthralgia (34%), alopecia (16%)
Clinical Conclusion
Palbociclib plus letrozole combination represents an effective first-line standard for postmenopausal women with ER-positive advanced breast cancer.
Data Source
PALOMA-2: Phase III trial of palbociclib with letrozole versus letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer. ASCO 2016, Abstract 706.
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3